# EDGAR Filing Document

**Accession Number:** 0001949257
**File Stem:** 0001213900-26-003148
**Filing Date:** 2026-1
**Character Count:** 8405
**Document Hash:** 78615a28cf15cd42e81735582ff948a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-003148.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001213900-26-003148

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260112

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Radiopharm Theranostics Ltd
- **CENTRAL INDEX KEY:** 0001949257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41621
- **FILM NUMBER:** 26524756

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 3 9824 5254

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of January 2026

Commission File Number: 001-41621

**<u>RADIOPHARM THERANOSTICS LIMITED</u>**

(Name of Registrant)

**<u>Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</u>**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

**RADIOPHARM THERANOSTICS LIMITED**

**<u>EXPLANATORY NOTE</u>**

Radiopharm Theranostics Limited (the "Company") published one announcement (the "Public Notice") to the Australian Securities Exchange on January 12, 2026 titled:

"RAD Increases Ownership in Radiopharm Ventures to 87.5%"

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** <br> **Number** | **Description** |
| 99.1 | [RAD Increases Ownership in Radiopharm Ventures to 87.5%](ea027252001ex99-1_radiopharm.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **RADIOPHARM THERANOSTICS LIMITED** | **RADIOPHARM THERANOSTICS LIMITED** |
| Date: January 12, 2026 | By: | /s/ Phillip Hains |
|  |  | Phillip Hains |
|  |  | Company Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> 12 JANUARY 2026**<br>| ![](ex99-1_001.jpg) |

---

**RAD Increases Ownership in Radiopharm Ventures to 87.5%**

● **Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics** 

● **Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026** 

● **First clinical trial globally targeting B7H3 with a systemic radiopharmaceutical** 

● **Two additional preclinical Radiopharm Ventures' assets show early positive results with plans to move to final candidate selection in 2026** 

Sydney, Australia – 12 January 2026 – Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, is pleased to announce that it has increased its ownership stake in Radiopharm Ventures, LLC, a joint venture created with The University of Texas MD Anderson Cancer Center (MDACC), from 75% to 87.5%.

Radiopharm's decision to increase the ownership percentage comes as the joint venture continues to show promising progress in its cancer therapeutic pipeline, including the advancement of its leading B7H3 candidate and other preclinical assets.

B7H3 is an immune checkpoint protein that is very infrequently seen in healthy cells but is consistently overexpressed in the majority of cancer tissues. High expression of B7H3 in cancer is associated with greater tumor size and lymphatic invasion.

Riccardo Canevari, CEO & Managing Director of Radiopharm, commented: "We are very encouraged by the progress to date within Radiopharm Ventures. Now is an exciting time to increase our ownership in the joint venture, as we will soon have first-in-human results of Betabart (RV01) from our dose escalating therapeutic Phase I study. We remain confident in the potential value of this program and its potential to benefit patients battling a multitude of solid tumor cancers."

The lead candidate monoclonal antibody (mAb) radiolabelled with <sup>177</sup>Lu, Betabart, targets B7H3 and successfully received Investigational New Drug clearance in July 2025 by the U.S. Food and Drug Administration. The first patient in this Phase 1 therapeutic trial is expected to be dosed in Q1 2026, with a number of centers already activated.

Additionally, two other preclinical candidates have demonstrated early positive results and have progressed towards final candidate selection, with potential applications across multiple solid tumor types.

Radiopharm and MDACC launched Radiopharm Ventures, LLC in September 2022 to develop novel radiopharmaceutical products for cancer treatment. The joint venture leverages MD Anderson's expertise in antigen discovery and molecular imaging alongside Radiopharm's capabilities in developing targeted radiopharmaceutical therapies.

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> 12 JANUARY 2026**<br>| ![](ex99-1_001.jpg) |

---

**About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers, including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

**Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari<br> CEO & Managing Director<br> P: +1 862 309 0293<br> E: rc@radiopharmtheranostics.com

Anne Marie Fields

Precision AQ (Formerly Stern IR)

E: annemarie.fields@precisionaq.com

Paul Hopper<br> Executive Chairman<br> P: +61 406 671 515<br> E: paulhopper@lifescienceportfolio.com

<u>Media</u><br> Matt Wright<br> NWR Communications

P: +61 451 896 420<br> E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:** 

Website – https://radiopharmtheranostics.com/<br> Twitter – https://twitter.com/TeamRadiopharm<br> Linked In – https://www.linkedin.com/company/radiopharm-theranostics/<br> InvestorHub – https://investorhub.radiopharmtheranostics.com/

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**